Energy company plans further investments here.
To HUF 570 per share from HUF 600.
Three more to go. Testing new concepts.
J.P. Morgan also cuts rating.
Spar spends EUR 2.5 mn on them.
It does not plan expansion, either.
U.S. FDA rejects application by Allergan.
Plaza ban is now stricter.